KRAS and familial pancreatic carcinoma: The expression of leukemia inhibitory factor receptor (LIFR) was significantly lower in pancreatic cancer compared to some cancers, but inhibition of KRAS mutation upregulated LIFR expression and was accompanied by a decrease in GLUT1 expression.